➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Johnson and Johnson
Colorcon
Express Scripts
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 7,655,221

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,655,221
Title:Methods of treating disease with random copolymers
Abstract: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.
Inventor(s): Rasmussen; James (Cambridge, MA), Zhang; Jianxin (Acton, MA), Baldwin; Sam (Westford, MA), Zanelli; Eric (Sudbury, MA), Yu; Bei (West Roxbury, MA), Bonnin; Dustan (Belmont, MA), Johnson; Keith (Hudson, MA)
Assignee: Peptimmune, Inc. (Cambridge, MA)
Application Number:11/283,406
Patent Claims:see list of patent claims

Details for Patent 7,655,221

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Pharmacia And Upjohn Company Llc ATGAM equine thymocyte immune globulin INJECTION, SOLUTION 103676 1 1981-11-17   Start Trial Peptimmune, Inc. (Cambridge, MA) 2024-05-07 search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial Peptimmune, Inc. (Cambridge, MA) 2024-05-07 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial Peptimmune, Inc. (Cambridge, MA) 2024-05-07 RX search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Peptimmune, Inc. (Cambridge, MA) 2024-05-07 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Peptimmune, Inc. (Cambridge, MA) 2024-05-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Mallinckrodt
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.